These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9578170)

  • 1. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime.
    De Boeck K; Breysem L
    J Antimicrob Chemother; 1998 Mar; 41(3):407-9. PubMed ID: 9578170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
    De Boeck K; Smet M; Eggermont E
    Pediatr Pulmonol; 1989; 7(3):171-3. PubMed ID: 2508049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
    Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
    Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.
    Kerem E; Corey M; Gold R; Levison H
    J Pediatr; 1990 May; 116(5):714-9. PubMed ID: 2109790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pulmonary Pseudomonas aeruginosa infection in cystic fibrosis with cefsulodin.
    Møller NE; Koch C; Vesterhauge S; Jensen K
    Scand J Infect Dis; 1982; 14(3):207-11. PubMed ID: 6815787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime in cystic fibrosis: clinical, microbiological and immunological studies.
    Cullen RT; McCrae WM; Govan J; Raeburn JA; Ingram TM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():369-75. PubMed ID: 6352647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Padoan R; Brienza A; Crossignani RM; Lodi G; Giunta A; Assael BM; Granata F; Passarella E; Vallaperta PA; Xerri L
    J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Stenvang Pedersen S; Pressler T; Pedersen M; Høiby N; Friis-Møller A; Koch C
    Scand J Infect Dis; 1986; 18(2):133-7. PubMed ID: 3518048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbenicillin treatment of Pseudomonas pulmonary infection. Use in children with cystic fibrosis.
    Phair JP; Tan JS; Watanakunakorn C; Schwab L; Sanders LW
    Am J Dis Child; 1970 Jul; 120(1):22-5. PubMed ID: 4316325
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
    Hauber HP; Schulz M; Pforte A; Mack D; Zabel P; Schumacher U
    Int J Med Sci; 2008; 5(6):371-6. PubMed ID: 19043609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
    Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis.
    Schryvers AB; Ogunariwo J; Chamberland S; Godfrey AJ; Rabin HR; Bryan LE
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1438-9. PubMed ID: 3118800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of pyocyanic bacillus superinfections in children with cystic fibrosis using a new cephalosporin: ceftazidime].
    Labbé A; Sablayrolles B; Dechamps C; Sirot J; Marty N
    Ann Pediatr (Paris); 1986 Sep; 33(7):625-8. PubMed ID: 3096185
    [No Abstract]   [Full Text] [Related]  

  • 16. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
    Padoan R; Cambisano W; Costantini D; Crossignani RM; Danza ML; Trezzi G; Giunta A
    Pediatr Infect Dis J; 1987 Jul; 6(7):648-53. PubMed ID: 3302917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoglycosides and renal magnesium homeostasis in humans.
    von Vigier RO; Truttmann AC; Zindler-Schmocker K; Bettinelli A; Aebischer CC; Wermuth B; Bianchetti MG
    Nephrol Dial Transplant; 2000 Jun; 15(6):822-6. PubMed ID: 10831634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Marley EF; Mohla C; Campos JM
    J Clin Microbiol; 1995 Dec; 33(12):3191-3. PubMed ID: 8586700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis.
    Amin R; Lam M; Dupuis A; Ratjen F
    Pediatr Pulmonol; 2011 Jun; 46(6):554-8. PubMed ID: 21337727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.